Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2191]

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory...

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

$CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )$

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )

Are PARP inhibitors a new standard of care option for MBC patients?

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Cancer care in Latin America

Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico

Cancer care in Latin America ( Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico )

Novel methods of drug testing and biopsy in India

Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India

Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA

Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )

Use of maintenance therapy following ASCT and real world treatment patterns in...

Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold

Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma ( Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold )

Comment: Laparoscopic versus open resection for colorectal liver metastases

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: Laparoscopic versus open resection for colorectal liver metastases ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Expanding clinical trial eligibility criteria: Risks and solutions

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

ASCO 2019 and vision for cancer control

Dr Eduardo Cazap - Editor-in-Chief, ecancer

ASCO 2019 and vision for cancer control ( Dr Eduardo Cazap - Editor-in-Chief, ecancer )

More from ecancer